[go: up one dir, main page]

US20120186988A1 - Method for producing a radioactively marked carboxylate - Google Patents

Method for producing a radioactively marked carboxylate Download PDF

Info

Publication number
US20120186988A1
US20120186988A1 US13/387,921 US201013387921A US2012186988A1 US 20120186988 A1 US20120186988 A1 US 20120186988A1 US 201013387921 A US201013387921 A US 201013387921A US 2012186988 A1 US2012186988 A1 US 2012186988A1
Authority
US
United States
Prior art keywords
carboxylate
carbon dioxide
radioactively labeled
solvent
microstructure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/387,921
Inventor
Markus Kinzl
Oliver Lade
Christian P. Schultz
Arno Steckenborn
Frank Thalmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens AG
Original Assignee
Siemens AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens AG filed Critical Siemens AG
Assigned to SIEMENS AKTIENGESELLSCHAFT reassignment SIEMENS AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHULTZ, CHRISTIAN, LADE, OLIVER, STECKENBORN, ARNO, THALMANN, FRANK, KINZL, MARKUS
Publication of US20120186988A1 publication Critical patent/US20120186988A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C25ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25BELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00Electrolytic production of organic compounds
    • C25B3/20Processes
    • C25B3/25Reduction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/141Feedstock

Definitions

  • the present invention relates to the technical field of radioactively labeled carbon compounds.
  • the present invention relates to a method for producing a radioactively labeled carboxylate.
  • Positron emission tomography is a method in nuclear medicine which produces sectional images of living organisms. During PET, the distribution of a radioactively labeled substance, a radiopharmakon, in the organism is shown, by which the structure and also biochemical and physiological processes are illustrated. A radiopharmakon is labeled by a radionuclide, a radioactive atom or isotope.
  • PET uses radioactively labeled substances which give off positron radiation.
  • positron radiation In the event of interaction of a positron with an electron in the body, two high-energy photons are emitted in opposite directions.
  • the principle of PET resides in recording these coinciding photons by detectors which face one another. The distribution in respect of time and space of these registered decay events is used to deduce the spatial distribution of the radiopharmakon in the body.
  • PET A frequent application of PET is in metabolic diseases, particularly in oncology, neurology and cardiology.
  • the radiopharmakon is enriched by many aggressive tumors, meaning that PET is suitable e.g. for the diagnosis, stage determination and progression monitoring of cancer diseases.
  • PET can be used to illustrate the circulation and thus the metabolic activity of neuronal and cardiac tissue.
  • PET can be used to detect chronically poorly vascularized areas within the heart muscle.
  • the organism does not differentiate between radiopharmakons and the corresponding non-radioactive compounds, meaning that radiopharmakons are metabolized normally. On account of the decay of the radionuclide, the radiopharmakon can be traced and visualized.
  • the radionuclides used most often are radioactive isotopes of the elements carbon ( 11 C), fluorine ( 18 F), nitrogen ( 13 N) and oxygen ( 15 O). These radionuclides are produced in a cyclotron by particle acceleration.
  • the usefulness of radiopharmakons is limited by the short half-life of the radionuclides of typically less than 2 hours.
  • the radionuclide 11 C has a particularly short half-life at only ca. 20 minutes.
  • the undesired decay in radioactivity starts as early as during the production of the radionuclide in the cyclotron and continues during the production of the radiopharmakon, its delivery to the PET site and finally to the point of administration to the patients and measurement.
  • the highest possible radioactivity of the radiopharmakon after its production must be present. This can be achieved by the shortest possible production time of the radiopharmakon from the radionuclide since the decay of the radioactivity of a radionuclide depends on the time.
  • the basis for producing a radiopharmakon is a molecule that is biochemically or physiologically active in the organism and in whose chemical structure one or more radionuclides are incorporated.
  • Conventional methods utilize the route via the methylating agent 11 CH 3 I, in order, for example, to radioactively label amines or carboxylic acids with 11 C (Denutte et al., 1983; Vandersteene and Slegers, 1996).
  • the 11 CO 2 produced in the cyclotron has to be further reacted in a two-stage process with LiAlH 4 and HI to give 11 CH3I. Only in a third step can the radioactively labeled methylating agent be transferred to the pharmakon to be labeled.
  • a high proportion of the radioactivity originally provided by the 11 CO 2 is lost.
  • Radiopharmakons labeled with fluorine e.g. 18 F-fluorouracil, 18 F-6-fluoro-DOPA or 18 F-fluoro-2-deoxy-D-glucose, however, differ from their corresponding non-labeled origin molecules, and so it is desired to use hydrocarbon compounds which do not differ chemically from their origin molecules.
  • the inventors propose a use of radioactively labeled carbon dioxide for the electrochemical synthesis of a radioactively labeled carboxylate, where the carbon dioxide during the synthesis is completely dissolved in a solvent.
  • the inventors propose a use of a microelectrode for the electrochemical synthesis of a radioactively labeled carboxylate, where radioactively labeled carbon dioxide is reacted.
  • FIG. 1 shows an electrochemical reductive carboxylation of a ketone with incorporation of 11 CO 2 for the synthesis of a radioactively labeled alpha- 11 C-amino acid.
  • FIG. 2 shows an electrochemical reductive carboxylation of a ketone with incorporation of 11 CO 2 for the synthesis of a radioactively labeled alpha- 11 C-hydroxy acid.
  • FIG. 3 shows a reductive carboxylation for producing an amino acid by reacting an imine with a radioactively labeled cyanide.
  • FIG. 4 shows two microelectrodes, cathode 1 and anode 3 , and also their arrangement relative to one another.
  • carboxylate refers to a compound which includes a carboxyl group, e.g. of the empirical formula R 1 R 2 R 3 C(COO ⁇ ).
  • the radicals R 1 , R 2 , R 3 bonded to the central carbon atom can be identical or different saturated or unsaturated linear, branched or cyclic aliphatic, aromatic or heteroaromatic radicals or mixed forms thereof. It is a prerequisite that the radicals do not contain groups which are themselves reactive under the carboxylation conditions.
  • the carboxylate includes in particular carboxylate amides, imides, anhydrides, carboxylic esters, carboxylic halides, aldehydes, ketones, amino acid salts, hydroxy acid salts, urethanes and carboxylic acid.
  • precursor molecules refers to starting substances and starting compounds of the carboxylate synthesis, such as e.g. imines or carbonyl compounds (cf. FIGS. 1 to 3 ).
  • conductive salt refers to an electrolyte dissolved in the solvent which conveys current.
  • reactants includes chemical molecules, such as carbon dioxide, cyanide, water and ammonia, and also protons and electrons.
  • the introduction of the reactants into the solvent can take place in one or more steps, meaning that the reactants can be introduced simultaneously, with an overlap or in succession.
  • electrochemically refers to a chemical reaction by electrolysis.
  • dissolved carbon dioxide refers to both physically dissolved carbon dioxide and also to hydrogen carbonate.
  • completely dissolved means that no gas phase arises in the solvent.
  • the term likewise refers to the complete saturation of the solvent with carbon dioxide. The complete dissolution can take place by predissolving the carbon dioxide prior to the start of the reaction under very high pressure in the solvent.
  • the rapid radioactive decay of radioactive 11 C hitherto made it necessary for an extremely high dose of radioactive starting substances to be used for the synthesis of the carboxylate radiopharmakon.
  • the dose of radioactive carbon which is used during the carboxylate synthesis can be reduced. This saves costs, and the radioactive burden of the radiochemist during the production of the radioactively labeled carboxylate is reduced.
  • reaction of the precursor molecule with the radioactively labeled carbon dioxide is very simple and can be carried out with low expenditure on apparatus. Intermediates do not have to be isolated or purified. The method can therefore be used directly in the clinic or the radiological surgery.
  • the reaction of the precursor molecule with radioactively labeled carbon dioxide takes place by a reductive electrochemical carboxylation via a short and rapid synthesis route.
  • the radioactively labeled carbon dioxide is incorporated into the precursor molecule during the last step of the carboxylate synthesis, i.e. only one synthesis step before the carboxylate end product (cf. FIGS. 1 and 2 ).
  • the carboxylation and also the labeling take place in a single step, which is not followed by any other synthesis steps.
  • EP 0 189 120 A1 A carboxylate synthesis with carbon dioxide is described in EP 0 189 120 A1, although no radioactively labeled carbon dioxide is used therein. Similarly, no completely dissolved carbon dioxide, but gaseous carbon dioxide, is used, meaning that in EP 0 189 120 A1 the yield is lower and the reaction time is longer. Since EP 0 189 120 A1 does not relate to the production of radioactively labeled carboxylate, these disadvantages are less serious since non-radioactive carboxylate does not decay as a function of time, but is stable. Moreover, the amount of starting substances used in EP 0 189 120 A1 is not a critical factor because no radioactive burden occurs.
  • the carboxylate is an alpha-hydroxy acid salt and/or an alpha-amino acid salt.
  • alpha- refers to the position of the carboxyl group on the alpha-carbon atom to which the hydroxyl group or amino group is also attached.
  • the alpha-hydroxy acid salt is synthesized in a single-stage reaction directly from a ketone or an aldehyde, with incorporation of the radioactively labeled carbon dioxide ( FIG. 1 ). It is therefore a very rapid and simple reaction with low radiochemical yield losses due to natural decay. It is therefore possible to reduce the dose of the radioactive carbon dioxide used and thus to reduce the radioactive burden.
  • the precursor molecule for producing the alpha-amino acid salt is synthesized by the first part of the established Strecker reaction ( FIGS. 1 and 3 ).
  • Alpha-amino acid salts can be synthesized by the method with a higher yield than alpha-hydroxy acid salts.
  • Alpha-amino acid salts, just like alpha-hydroxy acid salts and acids thereof, are physiologically important molecules that are widespread in the metabolism, meaning that they are customary PET biomarkers with diverse use.
  • the precursor molecule comprises ketimine, aldimine, ketone, aldehyde and/or ions thereof.
  • Aldimine has the formula R 1 HCNR 2 , ketimine the formula R 1 R 2 CNR 3 , ketone the formula R 1 R 2 CO and aldehyde the formula R 1 HCO.
  • a ketimine ion is an iminium cation ( FIG. 3 ).
  • the radicals R 1 , R 2 and R 3 can either be identical or different aromatic, heteroaromatic and aliphatic radicals.
  • the aliphatic radicals include acyclic branched and unbranched, cyclic and alicyclic, saturated and unsaturated carbon compounds. It is a prerequisite that the radicals do not contain groups which are themselves reactive under the carboxylation conditions.
  • the conductive salt comprises alkali metal halide, alkaline earth metal halide, ammonium halide, alkyl, cycloalkyl, arylammonium salt or quaternary ammonium salts, in particular tetra(C 1 -C 4 )alkylammonium tetrafluoroborate or tetra(C 1 -C 4 )alkylammonium hexafluorophosphate.
  • the radicals bonded to the nitrogen of the quaternary ammonium salt are identical or different aliphatic, cycloaliphatic or aromatic radicals.
  • Chloride, bromide, iodide, tetrafluoroborate, hexafluorophosphate, para-toluenesulfonate, perchlorate and bis(trifluoromethylsulfonimide) are preferred anions of the quaternary ammonium salts.
  • Tetra(C 1 -C 4 )alkylammonium tetrafluoroborate or hexafluorophosphate are preferred conductive salts, such as e.g. tetrabutylammonium tetrafluoroborate.
  • the solvent is an organic solvent.
  • Preferred solvents are amide, nitrile, N,N-dimethylformamide (DMF) and/or an open-chain or cyclic ether.
  • the reactant reacts with the precursor molecule in one step to give the carboxylate. Consequently, the reaction time is short and the radioactive yield losses over the period are low.
  • the radioactively labeled carbon dioxide is 11 CO 2 .
  • the carbon dioxide is introduced into the solvent under a pressure of more than 2 bar, preferably 5 bar or more than 5 bar. As a result of this high pressure, the carbon dioxide during the reaction of the precursor molecule is dissolved completely in the solvent.
  • the reaction takes place in a continuous-flow reactor.
  • the continuous-flow reactor is operated in a continuous procedure, as a result of which the reaction equilibrium is shifted in the synthesis direction. This leads to a high yield, to a high selectivity and also to a low concentration of undesired by-products.
  • microstructure refers to miniaturized units and systems both in the micrometer and also in the nanometer range, such as e.g. microcontainers, micromixers, microelectrodes and microstirrers.
  • microstructure ensures an improved surface/volume ratio of the reaction space.
  • the improved surface/volume ratio leads to a rapid mixing, an effective heat and current transfer and short controllable residence times of the solvent and also of the substances present therein. Methods using microstructures can therefore be operated more efficiently and lead to short reaction times and high yields.
  • microstructure used in the method therefore reduces the radiation burden and also the burden due to health-endangering substances to the radiochemist during the synthesis of the radioactively labeled carboxylate.
  • the microstructure includes at least one microelectrode.
  • the reduction can take place electrochemically with the help of microelectrodes.
  • a sacrificial anode serves as electron donor, meaning that the use of toxic cyanide or hydrogen cyanide as electron donor can be dispensed with.
  • the method can be operated with high yield and high selectivity.
  • the microelectrode comprises a microanode or microcathode.
  • Anode materials are soluble metals, in particular aluminum, magnesium, zinc, copper or alloys thereof, with aluminum and magnesium being most preferred.
  • Preferred cathode materials are conductive materials, such as conductive carbon materials, e.g. graphite, carbon fiber web and glassy carbon, and also nickel and magnesium, with magnesium being most preferred.
  • Particularly preferred combinations of anode and cathode are magnesium-magnesium and magnesium-carbon combinations.
  • the microelectrodes can be arranged close to one another. As a result of the spatial proximity, the field strength increases for the same voltage, meaning that it is possible to work with lower voltages for the same field strength.
  • the potential difference between the microelectrodes depends on the reacted molecules and is ascertained experimentally by analytical methods.
  • the electrolysis can be operated between the microelectrodes galvanostatically, although a potentiostatic procedure is preferred on account of the small amounts and volumes of solvent, conductive salt, reactant and precursor molecule.
  • the microstructure comprises two microelectrodes which are located in an undivided space.
  • the undivided electrode space has the advantage that the product selectivity is increased as a result of the salt formation with the cation of the dissolving sacrificial anode.
  • the salt formation protects against undesired secondary reactions, e.g. a reduction of the precursor molecules to give pinacol derivatives.
  • no ohmic resistance is built up as a result of a separation membrane.
  • the microelectrode comprises a coating, a tubular module, e.g. a microcapillary, a linear element, e.g. a wire, a two-dimensional lattice, a two-dimensional surface or a three-dimensional mesh.
  • a tubular module e.g. a microcapillary
  • a linear element e.g. a wire, a two-dimensional lattice, a two-dimensional surface or a three-dimensional mesh.
  • the tubular module is a cathode 1 and the linear element is an anode 3 .
  • the anode 3 is arranged centrally inside the cathode 1 .
  • the cathode 1 and the anode 3 are arranged relative to one another such that the longitudinal direction of the cathode 1 and the longitudinal direction of the anode 3 run parallel to one another ( FIG. 4 ).
  • the two-dimensional surface is in each case an anode and a cathode which are arranged on the opposite walls of a rectangular microstructure.
  • An arrangement of a two-dimensional anode and cathode on the opposite walls of a flat rectangular microstructure advantageously combines a homogeneous field in the electrode space with favorable flow ratios of the reactants, as a result of which the electrochemical reaction is configured more efficiently and the reaction time is reduced. Moreover, the yield is increased with simultaneous minimization of the secondary reactions due to a homogeneous residence time in this microstructure.
  • the reaction temperature is 20° C. to 30° C.
  • the concentration of the precursor molecule in the solvent is 0.1 M.
  • the method further involves the step of the acidic hydrolyzation of at least one carboxyl group of the carboxylate.
  • the acidic hydrolysis e.g. by hydrochloric acid
  • the carboxylate with the addition of a proton
  • the corresponding carboxylic acid is obtained, from the amino acid salt the corresponding amino acid is obtained and from the hydroxy acid salt the corresponding hydroxy acid is obtained.
  • the method involves the step of isolation of the carboxylic acid from the solvent.
  • the isolation preferably takes place by precipitation, filtration, evaporation, preparative chromatography and/or decantation and likewise involves the separation off from the conductive salt and desired and undesired by-products.
  • the precipitation takes place for example by a low-polarity solvent.
  • the acid function of the carboxylic acid can be derivatized, e.g. with methanol and sulfuric acid.
  • the carboxylic acid can also be analyzed, e.g. by chromatography, in particular by gas chromatography.
  • FIG. 3 shows by way of example the reductive carboxylation using cyanide.
  • the inventors propose a use of radioactively labeled carbon dioxide for the electrochemical synthesis of a radioactively labeled carboxylate, where the carbon dioxide during the synthesis is completely dissolved in a solvent.
  • the inventors propose a use of a microelectrode for the electrochemical synthesis of a radioactively labeled carboxylate, where radioactively labeled carbon dioxide is reacted.
  • FIG. 1 shows the synthesis of an alpha-amino acid by reductive electrochemical carboxylation.
  • the precursor molecule an iminium cation of the formula (R 1 R 2 C(NH 2 )) + , is synthesized for example by the Strecker synthesis from a ketone, R 1 R 2 O, with ammonia and hydrogen with the elimination of water.
  • the iminium cation is reduced by absorbing two electrons and, by adding radioactively labeled carbon dioxide, is reacted to give an amino acid salt, R 1 R 2 (H 2 N) 11 C(COO ⁇ ), as a result of which the carbon atom of the carboxyl group becomes radioactively labeled.
  • the carboxyl group is further hydrolyzed with the addition of a proton, meaning that the amino acid salt is reacted to give the amino acid. In the case of this synthesis, it is possible to dispense with protecting the acidic protons.
  • FIG. 2 shows the synthesis of an alpha-hydroxy acid by reductive electrochemical carboxylation.
  • the precursor molecule is a ketone, R 1 R 2 CO, which is reduced by absorbing two electrons and, by adding radioactively labeled carbon dioxide, is reacted to give an alpha-hydroxy acid salt, R 1 R 2 HO 11 C(COO ⁇ ).
  • the alpha-hydroxy acid salt is hydrolyzed to the alpha-hydroxy acid by adding a proton.
  • FIG. 3 shows the synthesis of a radioactively labeled nitrile from an imine with the incorporation of a proton and also radioactively labeled cyanide, 11 CN ⁇ .
  • the radioactively labeled nitrile can be hydrolyzed further to give an amino acid.
  • FIG. 4 shows an embodiment of an electrochemical micro continuous-flow reactor which has a capillary tube, the inside tube wall of which constitutes the cathode 1 . Furthermore, the micro continuous-flow reactor has a wire, the anode 3 , located centrally in the capillary tube.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method produces a radioactively marked carboxylate, at least one precursor molecule of the carboxylate being prepared in a solvent including a conductive salt. Radioactively marked carbon dioxide is fed into the solvent. The precursor molecule is electrochemically reacted with the radioactively marked carbon dioxide to form the radioactively marked carboxylate. The radioactively marked carbon dioxide is completely dissolved in the solvent when the precursor molecule is reacted. The radioactively marked carbon dioxide is used for electrochemically synthesizing a radioactively marked carboxylate, the carbon dioxide being completely dissolved in a solvent during synthesis. A microstructure is used for electrochemically synthesizing the radioactively marked carboxylate, radioactively marked carbon dioxide being reacted.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is based on and hereby claims priority to International Application No. PCT/EP2010/059726 filed on Jul. 7, 2010 and German Application No. 10 2009 035 648.7 filed on Jul. 29, 2009, the contents of which are hereby incorporated by reference.
  • BACKGROUND
  • The present invention relates to the technical field of radioactively labeled carbon compounds. In particular, the present invention relates to a method for producing a radioactively labeled carboxylate.
  • Positron emission tomography (PET) is a method in nuclear medicine which produces sectional images of living organisms. During PET, the distribution of a radioactively labeled substance, a radiopharmakon, in the organism is shown, by which the structure and also biochemical and physiological processes are illustrated. A radiopharmakon is labeled by a radionuclide, a radioactive atom or isotope.
  • In contrast to conventional scintigraphy, PET uses radioactively labeled substances which give off positron radiation. In the event of interaction of a positron with an electron in the body, two high-energy photons are emitted in opposite directions. The principle of PET resides in recording these coinciding photons by detectors which face one another. The distribution in respect of time and space of these registered decay events is used to deduce the spatial distribution of the radiopharmakon in the body.
  • A frequent application of PET is in metabolic diseases, particularly in oncology, neurology and cardiology. The radiopharmakon is enriched by many aggressive tumors, meaning that PET is suitable e.g. for the diagnosis, stage determination and progression monitoring of cancer diseases. Similarly, PET can be used to illustrate the circulation and thus the metabolic activity of neuronal and cardiac tissue. Similarly, PET can be used to detect chronically poorly vascularized areas within the heart muscle.
  • The organism does not differentiate between radiopharmakons and the corresponding non-radioactive compounds, meaning that radiopharmakons are metabolized normally. On account of the decay of the radionuclide, the radiopharmakon can be traced and visualized.
  • The radionuclides used most often are radioactive isotopes of the elements carbon (11C), fluorine (18F), nitrogen (13N) and oxygen (15O). These radionuclides are produced in a cyclotron by particle acceleration.
  • The usefulness of radiopharmakons is limited by the short half-life of the radionuclides of typically less than 2 hours. The radionuclide 11C has a particularly short half-life at only ca. 20 minutes. The undesired decay in radioactivity starts as early as during the production of the radionuclide in the cyclotron and continues during the production of the radiopharmakon, its delivery to the PET site and finally to the point of administration to the patients and measurement.
  • In order to achieve the widest possible supply radius in which the positron emission tomograph to be supplied is located around the cyclotron, the highest possible radioactivity of the radiopharmakon after its production must be present. This can be achieved by the shortest possible production time of the radiopharmakon from the radionuclide since the decay of the radioactivity of a radionuclide depends on the time.
  • The basis for producing a radiopharmakon is a molecule that is biochemically or physiologically active in the organism and in whose chemical structure one or more radionuclides are incorporated. Conventional methods utilize the route via the methylating agent 11CH3I, in order, for example, to radioactively label amines or carboxylic acids with 11C (Denutte et al., 1983; Vandersteene and Slegers, 1996). However, in this process, the 11CO2 produced in the cyclotron has to be further reacted in a two-stage process with LiAlH4 and HI to give 11CH3I. Only in a third step can the radioactively labeled methylating agent be transferred to the pharmakon to be labeled. As a result of this laborious synthesis of the radiopharmakon, a high proportion of the radioactivity originally provided by the 11CO2 is lost.
  • Important technology has been introduced for new PET contrast agents in the field of 18F labeling by so-called “click chemistry”. This method permits the synthesis of radioactive contrast agents in a single step (Devaraj et al., 2009; Li et al., 2007). Radiopharmakons labeled with fluorine, e.g. 18F-fluorouracil, 18F-6-fluoro-DOPA or 18F-fluoro-2-deoxy-D-glucose, however, differ from their corresponding non-labeled origin molecules, and so it is desired to use hydrocarbon compounds which do not differ chemically from their origin molecules.
  • SUMMARY
  • It was therefore one possible object to provide an efficient method by which a radioactively labeled hydrocarbon compound can be synthesized within a short production time with high yield.
  • The inventors propose a method for producing a radioactively labeled carboxylate which involves:
      • provision of at least one precursor molecule of the carboxylate in a solvent which comprises a conductive salt;
      • introduction of at least one reactant which comprises radioactively labeled carbon dioxide into the solvent; and
      • electrochemical reaction of the precursor molecule with the radioactively labeled carbon dioxide to give the radioactively labeled carboxylate;
        where the radioactively labeled carbon dioxide during the reaction of the precursor molecule is completely dissolved in the solvent.
  • In addition, the inventors propose a use of radioactively labeled carbon dioxide for the electrochemical synthesis of a radioactively labeled carboxylate, where the carbon dioxide during the synthesis is completely dissolved in a solvent.
  • In addition, the inventors propose a use of a microelectrode for the electrochemical synthesis of a radioactively labeled carboxylate, where radioactively labeled carbon dioxide is reacted.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and other objects and advantages of the present invention will become more apparent and more readily appreciated from the following description of the preferred embodiments, taken in conjunction with the accompanying drawings of which:
  • FIG. 1 shows an electrochemical reductive carboxylation of a ketone with incorporation of 11CO2 for the synthesis of a radioactively labeled alpha-11C-amino acid.
  • FIG. 2 shows an electrochemical reductive carboxylation of a ketone with incorporation of 11CO2 for the synthesis of a radioactively labeled alpha-11C-hydroxy acid.
  • FIG. 3 shows a reductive carboxylation for producing an amino acid by reacting an imine with a radioactively labeled cyanide.
  • FIG. 4 shows two microelectrodes, cathode 1 and anode 3, and also their arrangement relative to one another.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • Reference will now be made in detail to the preferred embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout.
  • A method for producing a radioactively labeled carboxylate involves:
      • provision of at least one precursor molecule of the carboxylate in a solvent which comprises a conductive salt;
      • introduction of at least one reactant which comprises radioactively labeled carbon dioxide into the solvent; and
      • electrochemical reaction of the precursor molecule with the radioactively labeled carbon dioxide to give the radioactively labeled carboxylate;
        where the radioactively labeled carbon dioxide during the reaction of the precursor molecule is completely dissolved in the solvent.
  • The term “carboxylate”, as used here, refers to a compound which includes a carboxyl group, e.g. of the empirical formula R1R2R3C(COO). The radicals R1, R2, R3 bonded to the central carbon atom can be identical or different saturated or unsaturated linear, branched or cyclic aliphatic, aromatic or heteroaromatic radicals or mixed forms thereof. It is a prerequisite that the radicals do not contain groups which are themselves reactive under the carboxylation conditions. The carboxylate includes in particular carboxylate amides, imides, anhydrides, carboxylic esters, carboxylic halides, aldehydes, ketones, amino acid salts, hydroxy acid salts, urethanes and carboxylic acid.
  • The term “precursor molecules”, as used here, refers to starting substances and starting compounds of the carboxylate synthesis, such as e.g. imines or carbonyl compounds (cf. FIGS. 1 to 3).
  • The term “conductive salt”, as used here, refers to an electrolyte dissolved in the solvent which conveys current.
  • The term “reactants”, as used here, includes chemical molecules, such as carbon dioxide, cyanide, water and ammonia, and also protons and electrons. The introduction of the reactants into the solvent can take place in one or more steps, meaning that the reactants can be introduced simultaneously, with an overlap or in succession.
  • The term “electrochemically”, as used here, refers to a chemical reaction by electrolysis.
  • The term “dissolved carbon dioxide” refers to both physically dissolved carbon dioxide and also to hydrogen carbonate. The term “completely dissolved”, as used here, means that no gas phase arises in the solvent. The term likewise refers to the complete saturation of the solvent with carbon dioxide. The complete dissolution can take place by predissolving the carbon dioxide prior to the start of the reaction under very high pressure in the solvent.
  • In the method for producing a radioactively labeled carboxylate, short reaction times and therefore production times, and also a high yield of the carboxylate, are achieved by dissolving the radioactively labeled carbon dioxide completely.
  • As a result of completely dissolving the carbon dioxide, its concentration in the solvent is increased. Concentration gradients due to an undissolved gas phase are avoided. The complete dissolution of the carbon dioxide leads to a better mixing and a homogeneous concentration of the carbon dioxide in the solvent. Overall, therefore, the reaction time and production time are shortened and the yield is increased.
  • As a result of the short reaction time and production time, radiochemical yield losses due to the natural decay of the radionuclide as a function of time are in turn reduced.
  • The rapid radioactive decay of radioactive 11C hitherto made it necessary for an extremely high dose of radioactive starting substances to be used for the synthesis of the carboxylate radiopharmakon. By shortening the reaction time by the method, the dose of radioactive carbon which is used during the carboxylate synthesis can be reduced. This saves costs, and the radioactive burden of the radiochemist during the production of the radioactively labeled carboxylate is reduced.
  • The reaction of the precursor molecule with the radioactively labeled carbon dioxide is very simple and can be carried out with low expenditure on apparatus. Intermediates do not have to be isolated or purified. The method can therefore be used directly in the clinic or the radiological surgery.
  • The reaction of the precursor molecule with radioactively labeled carbon dioxide takes place by a reductive electrochemical carboxylation via a short and rapid synthesis route. The radioactively labeled carbon dioxide is incorporated into the precursor molecule during the last step of the carboxylate synthesis, i.e. only one synthesis step before the carboxylate end product (cf. FIGS. 1 and 2). The carboxylation and also the labeling take place in a single step, which is not followed by any other synthesis steps.
  • A carboxylate synthesis with carbon dioxide is described in EP 0 189 120 A1, although no radioactively labeled carbon dioxide is used therein. Similarly, no completely dissolved carbon dioxide, but gaseous carbon dioxide, is used, meaning that in EP 0 189 120 A1 the yield is lower and the reaction time is longer. Since EP 0 189 120 A1 does not relate to the production of radioactively labeled carboxylate, these disadvantages are less serious since non-radioactive carboxylate does not decay as a function of time, but is stable. Moreover, the amount of starting substances used in EP 0 189 120 A1 is not a critical factor because no radioactive burden occurs.
  • In a preferred embodiment, the carboxylate is an alpha-hydroxy acid salt and/or an alpha-amino acid salt. The prefix “alpha-” refers to the position of the carboxyl group on the alpha-carbon atom to which the hydroxyl group or amino group is also attached.
  • The alpha-hydroxy acid salt is synthesized in a single-stage reaction directly from a ketone or an aldehyde, with incorporation of the radioactively labeled carbon dioxide (FIG. 1). It is therefore a very rapid and simple reaction with low radiochemical yield losses due to natural decay. It is therefore possible to reduce the dose of the radioactive carbon dioxide used and thus to reduce the radioactive burden.
  • The precursor molecule for producing the alpha-amino acid salt is synthesized by the first part of the established Strecker reaction (FIGS. 1 and 3). Alpha-amino acid salts can be synthesized by the method with a higher yield than alpha-hydroxy acid salts. Alpha-amino acid salts, just like alpha-hydroxy acid salts and acids thereof, are physiologically important molecules that are widespread in the metabolism, meaning that they are customary PET biomarkers with diverse use.
  • In a further embodiment, the precursor molecule comprises ketimine, aldimine, ketone, aldehyde and/or ions thereof. Aldimine has the formula R1HCNR2, ketimine the formula R1R2CNR3, ketone the formula R1R2CO and aldehyde the formula R1HCO. One example of a ketimine ion is an iminium cation (FIG. 3). The radicals R1, R2 and R3 can either be identical or different aromatic, heteroaromatic and aliphatic radicals. The aliphatic radicals include acyclic branched and unbranched, cyclic and alicyclic, saturated and unsaturated carbon compounds. It is a prerequisite that the radicals do not contain groups which are themselves reactive under the carboxylation conditions. These precursor molecules are cost-effective, commercially available and simple to produce using standard methods.
  • In a preferred embodiment, the conductive salt comprises alkali metal halide, alkaline earth metal halide, ammonium halide, alkyl, cycloalkyl, arylammonium salt or quaternary ammonium salts, in particular tetra(C1-C4)alkylammonium tetrafluoroborate or tetra(C1-C4)alkylammonium hexafluorophosphate. The radicals bonded to the nitrogen of the quaternary ammonium salt are identical or different aliphatic, cycloaliphatic or aromatic radicals. Chloride, bromide, iodide, tetrafluoroborate, hexafluorophosphate, para-toluenesulfonate, perchlorate and bis(trifluoromethylsulfonimide) are preferred anions of the quaternary ammonium salts. Tetra(C1-C4)alkylammonium tetrafluoroborate or hexafluorophosphate are preferred conductive salts, such as e.g. tetrabutylammonium tetrafluoroborate.
  • In a further embodiment, the solvent is an organic solvent. Preferred solvents are amide, nitrile, N,N-dimethylformamide (DMF) and/or an open-chain or cyclic ether.
  • In a further embodiment, the reactant reacts with the precursor molecule in one step to give the carboxylate. Consequently, the reaction time is short and the radioactive yield losses over the period are low.
  • In a further embodiment, the radioactively labeled carbon dioxide is 11CO2.
  • In a further embodiment, the carbon dioxide is introduced into the solvent under a pressure of more than 2 bar, preferably 5 bar or more than 5 bar. As a result of this high pressure, the carbon dioxide during the reaction of the precursor molecule is dissolved completely in the solvent.
  • In a further preferred embodiment, the reaction takes place in a continuous-flow reactor. The continuous-flow reactor is operated in a continuous procedure, as a result of which the reaction equilibrium is shifted in the synthesis direction. This leads to a high yield, to a high selectivity and also to a low concentration of undesired by-products.
  • In a further embodiment, the reaction takes place on a microstructure. The term “microstructure”, as used here, refers to miniaturized units and systems both in the micrometer and also in the nanometer range, such as e.g. microcontainers, micromixers, microelectrodes and microstirrers.
  • The use of the microstructure ensures an improved surface/volume ratio of the reaction space. The improved surface/volume ratio leads to a rapid mixing, an effective heat and current transfer and short controllable residence times of the solvent and also of the substances present therein. Methods using microstructures can therefore be operated more efficiently and lead to short reaction times and high yields.
  • The very good controllability of the syntheses on microstructures and the small amount of health-endangering solvents and also the toxic reactants present therein and in particular the radiopharmakons lead to high operational safety. The microstructure used in the method therefore reduces the radiation burden and also the burden due to health-endangering substances to the radiochemist during the synthesis of the radioactively labeled carboxylate.
  • During the method for producing a radioactively labeled carboxylate, short reaction times and therefore production times and also a high yield of the carboxylate are achieved by the carboxylation taking place on a microstructure. As a result of the short reaction and production time, radiochemical yield losses due to natural decay of the carbon radionuclide as a function of the time are reduced. The amount of carbon radionuclide used in the synthesis of the radioactively labeled carboxylate can therefore be reduced, as a result of which costs are saved and the burden to the radiochemist during the synthesis is reduced.
  • In a further embodiment, the microstructure includes at least one microelectrode.
  • During the carboxylation with carbon dioxide, the reduction can take place electrochemically with the help of microelectrodes. In this process, a sacrificial anode serves as electron donor, meaning that the use of toxic cyanide or hydrogen cyanide as electron donor can be dispensed with. As a result of the electrochemical catalysis, the method can be operated with high yield and high selectivity. Readily accessible compounds, such as aldehydes or ketones, serve as precursors.
  • The microelectrode comprises a microanode or microcathode. Anode materials are soluble metals, in particular aluminum, magnesium, zinc, copper or alloys thereof, with aluminum and magnesium being most preferred. Preferred cathode materials are conductive materials, such as conductive carbon materials, e.g. graphite, carbon fiber web and glassy carbon, and also nickel and magnesium, with magnesium being most preferred. Particularly preferred combinations of anode and cathode are magnesium-magnesium and magnesium-carbon combinations.
  • On account of their geometry, the microelectrodes can be arranged close to one another. As a result of the spatial proximity, the field strength increases for the same voltage, meaning that it is possible to work with lower voltages for the same field strength.
  • The potential difference between the microelectrodes depends on the reacted molecules and is ascertained experimentally by analytical methods. The electrolysis can be operated between the microelectrodes galvanostatically, although a potentiostatic procedure is preferred on account of the small amounts and volumes of solvent, conductive salt, reactant and precursor molecule.
  • In a further embodiment, the microstructure comprises two microelectrodes which are located in an undivided space. The undivided electrode space has the advantage that the product selectivity is increased as a result of the salt formation with the cation of the dissolving sacrificial anode. The salt formation protects against undesired secondary reactions, e.g. a reduction of the precursor molecules to give pinacol derivatives. Moreover, in undivided spaces, no ohmic resistance is built up as a result of a separation membrane.
  • In a further preferred embodiment, the microelectrode comprises a coating, a tubular module, e.g. a microcapillary, a linear element, e.g. a wire, a two-dimensional lattice, a two-dimensional surface or a three-dimensional mesh. As a result of these electrode variants, the surface/volume ratio is further improved.
  • In a particularly preferred embodiment, the tubular module is a cathode 1 and the linear element is an anode 3. The anode 3 is arranged centrally inside the cathode 1. The cathode 1 and the anode 3 are arranged relative to one another such that the longitudinal direction of the cathode 1 and the longitudinal direction of the anode 3 run parallel to one another (FIG. 4).
  • In a particularly preferred embodiment, the two-dimensional surface is in each case an anode and a cathode which are arranged on the opposite walls of a rectangular microstructure. An arrangement of a two-dimensional anode and cathode on the opposite walls of a flat rectangular microstructure advantageously combines a homogeneous field in the electrode space with favorable flow ratios of the reactants, as a result of which the electrochemical reaction is configured more efficiently and the reaction time is reduced. Moreover, the yield is increased with simultaneous minimization of the secondary reactions due to a homogeneous residence time in this microstructure.
  • In a particularly preferred embodiment, the reaction temperature is 20° C. to 30° C. In a further embodiment, the concentration of the precursor molecule in the solvent is 0.1 M.
  • In a further embodiment, the method further involves the step of the acidic hydrolyzation of at least one carboxyl group of the carboxylate. As a result of the acidic hydrolysis, e.g. by hydrochloric acid, from the carboxylate, with the addition of a proton, the corresponding carboxylic acid is obtained, from the amino acid salt the corresponding amino acid is obtained and from the hydroxy acid salt the corresponding hydroxy acid is obtained.
  • Furthermore, the method involves the step of isolation of the carboxylic acid from the solvent. The isolation preferably takes place by precipitation, filtration, evaporation, preparative chromatography and/or decantation and likewise involves the separation off from the conductive salt and desired and undesired by-products. The precipitation takes place for example by a low-polarity solvent. In a further step, the acid function of the carboxylic acid can be derivatized, e.g. with methanol and sulfuric acid. In a further step, the carboxylic acid can also be analyzed, e.g. by chromatography, in particular by gas chromatography.
  • In addition, the inventors propose a method for producing a radioactively labeled carboxylate, involving:
      • provision of at least one precursor molecule in a solvent;
      • addition of at least one reactant which comprises radioactively labeled cyanide to the solvent; and
      • reaction of the precursor molecule with the reactant to give the radioactively labeled carboxylate,
        where the reaction takes place on a microstructure.
  • FIG. 3 shows by way of example the reductive carboxylation using cyanide.
  • In addition, the inventors propose a use of radioactively labeled carbon dioxide for the electrochemical synthesis of a radioactively labeled carboxylate, where the carbon dioxide during the synthesis is completely dissolved in a solvent.
  • In addition, the inventors propose a use of a microelectrode for the electrochemical synthesis of a radioactively labeled carboxylate, where radioactively labeled carbon dioxide is reacted.
  • The above variants and embodiments in respect of the first subject matter also relate to the other subject matter.
  • The formula schemes in FIGS. 1 to 4 show selected examples of the carboxylation.
  • FIG. 1 shows the synthesis of an alpha-amino acid by reductive electrochemical carboxylation. The precursor molecule, an iminium cation of the formula (R1R2C(NH2))+, is synthesized for example by the Strecker synthesis from a ketone, R1R2O, with ammonia and hydrogen with the elimination of water. The iminium cation is reduced by absorbing two electrons and, by adding radioactively labeled carbon dioxide, is reacted to give an amino acid salt, R1R2(H2N)11C(COO), as a result of which the carbon atom of the carboxyl group becomes radioactively labeled. The carboxyl group is further hydrolyzed with the addition of a proton, meaning that the amino acid salt is reacted to give the amino acid. In the case of this synthesis, it is possible to dispense with protecting the acidic protons.
  • FIG. 2 shows the synthesis of an alpha-hydroxy acid by reductive electrochemical carboxylation. The precursor molecule is a ketone, R1R2CO, which is reduced by absorbing two electrons and, by adding radioactively labeled carbon dioxide, is reacted to give an alpha-hydroxy acid salt, R1R2HO11C(COO). The alpha-hydroxy acid salt is hydrolyzed to the alpha-hydroxy acid by adding a proton.
  • FIG. 3 shows the synthesis of a radioactively labeled nitrile from an imine with the incorporation of a proton and also radioactively labeled cyanide, 11CN. The radioactively labeled nitrile can be hydrolyzed further to give an amino acid.
  • FIG. 4 shows an embodiment of an electrochemical micro continuous-flow reactor which has a capillary tube, the inside tube wall of which constitutes the cathode 1. Furthermore, the micro continuous-flow reactor has a wire, the anode 3, located centrally in the capillary tube.
  • The invention has been described in detail with particular reference to preferred embodiments thereof and examples, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention covered by the claims which may include the phrase “at least one of A, B and C” as an alternative expression that means one or more of A, B and C may be used, contrary to the holding in Superguide v. DIRECTV, 69 USPQ2d 1865 (Fed. Cir. 2004).

Claims (22)

1-19. (canceled)
20. A method for producing a radioactively labeled carboxylate, comprising:
providing a precursor molecule of the carboxylate in a solvent which comprises a conductive salt;
introducing a reactant which comprises radioactively labeled carbon dioxide into the solvent;
electrochemically producing a reaction of the precursor molecule with the radioactively labeled carbon dioxide to produce the radioactively labeled carboxylate; and
completely dissolving the radioactively labeled carbon dioxide in the solvent before the reaction of the precursor molecule.
21. The method as claimed in claim 20, wherein
the carboxylate is an alpha-hydroxy acid salt and/or an alpha-amino acid salt.
22. The method as claimed in claim 20, wherein
the precursor molecule is selected from the group consisting of a ketimine, an aldimine, a ketone, an aldehyde and ions thereof.
23. The method as claimed in claim 20, wherein
the conductive salt is selected from the group consisting of an alkali metal halide, an alkaline earth metal halide, an ammonium halide, an alkyl-, cycloalkyl-, or aryl-ammonium salt, and a quaternary ammonium salt.
24. The method as claimed in claim 20, wherein
the conductive salt is selected from the group consisting of tetra(C1-C4)alkylammonium tetrafluoroborate and tetra(C1-C4)alkylammonium hexafluorophosphate.
25. The method as claimed in claim 20, wherein
the solvent is an organic solvent selected from the group consisting of an amide, a nitrile, N,N-dimethylformamide, an open-chain ether, and a cyclic ether.
26. The method as claimed in claim 20, wherein
the reactant is reacted with the precursor molecule in only one step to produce the carboxylate.
27. The method as claimed in claim 20, wherein
the radioactively labeled carbon dioxide is 11CO2.
28. The method as claimed in claim 20, wherein
the carbon dioxide is introduced into the solvent under a pressure of more than 2 bar.
29. The method as claimed in claim 20, wherein
the carbon dioxide is introduced into the solvent under a pressure of at least 5 bar.
30. The method as claimed in claim 20, wherein
the reaction takes place in a continuous-flow reactor.
31. The method as claimed in claim 20, wherein
the reaction takes place on a microstructure.
32. The method as claimed in claim 31, wherein
the microstructure comprises at least one microelectrode.
33. The method as claimed in claim 31, wherein
the microstructure comprises two microelectrodes which are located in an undivided space.
34. The method as claimed in claim 31, wherein
the microstructure is selected from the group consisting of a coating, a tubular module, a linear element, a two-dimensional lattice, a two-dimensional surface and a three-dimensional mesh.
35. The method as claimed in claim 31, wherein the microstructure comprises:
a tubular cathode; and
a linear anode arranged centrally inside the cathode, the cathode and the anode being arranged relative to one another such that a longitudinal direction of the cathode runs parallel to a longitudinal direction of the anode.
36. The method as claimed in claim 34, wherein
the reaction takes place in a rectangular microstructure,
the rectangular microstructure has opposing walls formed respectively of two dimensional surfaces, and
an anode and a cathode are formed respectively in the two-dimensional surfaces.
37. The method as claimed in claim 20, further comprising:
hydrolyzing a carboxyl group of the carboxylate to produce an acid.
38. The method as claimed in claim 20, further comprising:
hydrolyzing a carboxyl group of the carboxylate to produce a carboxylic acid; and
isolating the carboxylic acid from the solvent.
39. A use of radioactively labeled carbon dioxide for the electrochemical synthesis of a radioactively labeled carboxylate, wherein
the carbon dioxide is completely dissolved in a solvent during synthesis.
40. A use of a microelectrode for the electrochemical synthesis of a radioactively labeled carboxylate, wherein
radioactively labeled carbon dioxide is reacted.
US13/387,921 2009-07-29 2010-07-07 Method for producing a radioactively marked carboxylate Abandoned US20120186988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009035648.7 2009-07-29
DE102009035648A DE102009035648B3 (en) 2009-07-29 2009-07-29 A process for the preparation of a radiolabeled carboxylate and the use of a microelectrode for the electrochemical synthesis of a radiolabeled carboxylate
PCT/EP2010/059726 WO2011012413A1 (en) 2009-07-29 2010-07-07 Method for producing a radioactively marked carboxylate

Publications (1)

Publication Number Publication Date
US20120186988A1 true US20120186988A1 (en) 2012-07-26

Family

ID=42734782

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/387,921 Abandoned US20120186988A1 (en) 2009-07-29 2010-07-07 Method for producing a radioactively marked carboxylate

Country Status (6)

Country Link
US (1) US20120186988A1 (en)
EP (1) EP2459503A1 (en)
JP (1) JP2013500294A (en)
DE (1) DE102009035648B3 (en)
SG (1) SG178134A1 (en)
WO (1) WO2011012413A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194360A1 (en) 2022-04-07 2023-10-12 Danmarks Tekniske Universitet Co2 and co electrolysis to produce high purity isotopically labelled organic compounds

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009035649A1 (en) * 2009-07-29 2011-02-03 Siemens Aktiengesellschaft Drug and method for testing a drug
DE102010026053A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of neurons expressing an acetylcholine receptor
DE102010026059A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue that expresses a chemokine receptor
DE102010026060A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for detection of a tumor expressing a somatostatin receptor
DE102010026052A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue expressing an IGF receptor
DE102010026057A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft Diagnostic for the localization of a diseased tissue
DE102010026065A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for detection of a tumor expressing a bombesin receptor
DE102010026058A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of an antibody
DE102010026063A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue
DE102010026066A1 (en) 2010-06-30 2012-01-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. 11C-labeled aptamer for the detection of a diseased tissue
DE102010026054A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of an antigen
DE102010026064A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for the detection of a diseased tissue
DE102010026056A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for detection of a tumor expressing a peptide transporter
DE102010026061A1 (en) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-labeled peptide for detection of a tumor expressing a Her2 / neu receptor
DE102011118030A1 (en) 2011-06-08 2012-12-13 Siemens Aktiengesellschaft Preparation and use of a peptide having an N-terminal 11 C-labeled acetyl group
TWI504594B (en) * 2014-09-18 2015-10-21 Chang Chun Plastics Co Ltd Process for the epoxidation of olefins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500099A (en) * 1995-05-09 1996-03-19 Hoechst Celanese Corporation Process for the electrochemical oxidation of arylketones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55119185A (en) * 1979-03-09 1980-09-12 Ube Ind Ltd Manufacture of alpha-phenylglycine
JPS60100536A (en) * 1983-11-04 1985-06-04 Agency Of Ind Science & Technol Preparation of 2-(p-isobutylphenyl)propionic acid
IT1183279B (en) * 1985-01-21 1987-10-22 Consiglio Nazionale Ricerche ELECTROCARBOSSILATION PROCESS OF CARBONYL COMPOUNDS FOR THE PRODUCTION OF HYDROXY - CARBOXYLIC ACIDS
JPH0686672B2 (en) * 1990-07-09 1994-11-02 工業技術院長 Method for producing aromatic carboxylic acid
JP2828853B2 (en) * 1992-12-28 1998-11-25 住友重機械工業株式会社 Acetic acid synthesis method
DE102009035647A1 (en) * 2009-04-03 2010-10-07 Siemens Aktiengesellschaft Method for generating a radiopharmaceutical
JP5237880B2 (en) * 2009-04-30 2013-07-17 Jfeテクノス株式会社 Method and apparatus for producing labeled compound for PET using microchip

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500099A (en) * 1995-05-09 1996-03-19 Hoechst Celanese Corporation Process for the electrochemical oxidation of arylketones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bazrker at al, 1940, 26(8), Proceedings of the National Academy of Sciences. *
Chaussard et al, Journal of Applied Electrochemistry, 19, Scale-up of electrocarboxylation reactions with a consumable anode, 1989. *
House et al, Journal of Organic Chemistry, 36(16), 1971. *
ZIogas et al, Revews in Applied Electrochemistry, 68, 2009, 2297-2313. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194360A1 (en) 2022-04-07 2023-10-12 Danmarks Tekniske Universitet Co2 and co electrolysis to produce high purity isotopically labelled organic compounds

Also Published As

Publication number Publication date
WO2011012413A1 (en) 2011-02-03
SG178134A1 (en) 2012-03-29
DE102009035648B3 (en) 2011-03-17
JP2013500294A (en) 2013-01-07
EP2459503A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
US20120186988A1 (en) Method for producing a radioactively marked carboxylate
Schlyer PET tracers and radiochemistry
EP3663307B1 (en) Production method for radiolabeled aryl compound
US20210386873A1 (en) Precursor compound of radioactive halogen-labeled organic compound
US11779665B2 (en) Electrochemical flash fluorination and radiofluorination
US20090277804A1 (en) Electrochemical separation of [18f] fluoride from [180] water
US8937166B2 (en) 68Ga generator
US20100228060A1 (en) Perfluoro-aryliodonium salts in nucleophilic aromatic 18f-fluorination
EP2500338A1 (en) F-labeled azide compound, reagent for 18f-labeling and method for 18f-labeling of alkyne compound using same
Orlovskaya et al. Methods for the synthesis of fluorine-18-labeled aromatic amino acids, radiotracers for positron emission tomography (PET)
Baumeister et al. Steric influence of salicylaldehyde-based Schiff base ligands on the formation of trans-[Re (PR 3) 2 (Schiff base)]+ complexes
CN109320500A (en) A kind of 18F-labeled benzimidazole compound and its preparation method and application
Conway et al. Synthesis of “no-carrier-added” carbon-11 SarCNU: the sarcosinamide analog of the chemotherapeutic agent BCNU
US20100150835A1 (en) Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate
US10308664B2 (en) [18F] fluoride cryptate complexes for radiolabeling fluorinations
US8030526B2 (en) Simple, rapid method for the preparation of isotopically labeled formaldehyde
Gomzina et al. Methylation as a method for synthesis of radiopharmaceuticals for positron emission tomography
EP4491612A1 (en) Method for producing radiolabeled aryl compound by electrolytic oxidation reaction
KR101592291B1 (en) Method for preparing [18F]Fluoro-L-Dopa with high radiochemical and enantiomeric purity
RU2583371C1 (en) Method of producing o-(2'-[18f]fluoroethyl)-l-tyrosine
Fiel Pre-concentration of positron-emitting [18F] fluoride and radiosynthesis of fluoride-based prosthetic compounds for PET imaging using magnetic droplet microfluidics (MDM)
Luzi Novel 11C-methylation Strategies and Their Application in CNS Receptor Imaging
US20190389880A1 (en) [18F] Fluoride Cryptate Complexes for Radiolabeling Fluorinations
Castillo Meleán Radiosynthesis of [18F] fluorophenyl-L-amino acids by isotopic exchange on carbonyl-activated precursors
HK40111817A (en) Production method for radiolabeled aryl compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIEMENS AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KINZL, MARKUS;LADE, OLIVER;SCHULTZ, CHRISTIAN;AND OTHERS;SIGNING DATES FROM 20120103 TO 20120207;REEL/FRAME:028147/0035

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION